Blazing a trail for commercial TCR T cell therapy

Cell & Gene Therapy Insights 2022; 8(5), 603–609

DOI: 10.18609/cgti.2022.093

Published: 14 June 2022
Helen Tayton-Martin

Dr Helen Tayton-Martin has served as our Chief Business Officer since March 2017 and is a member of our Executive Team. She formerly served as our Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO. As our CBO, Dr Tayton-Martin is responsible for optimizing the strategic and commercial opportunity for Adaptimmune’s assets, leading on business development and alliance management. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis and partnerships, including the company’s strategic partnerships with GlaxoSmithKline (LSE/NYSE: GSK), Astellas and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Dr Tayton Martin has over 26 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for business development of the soluble TCR program in cancer and HIV from 2005 to 2008. Dr Tayton Martin previously served as a non executive director of Trillium Therapeutics Inc. (Nasdaq and TSX: TRIL) from October 2017 through the sale of the company in November 2021to Pfizer Inc. She holds a PhD in molecular immunology from the University of Bristol, UK and an MBA from London Business School.